CONNECT-FX trial open to 29 November 2019
Enrolments open until the end of July 2019:
The aim of the study is to determine whether Zygel can help manage some common behavioural symptoms associated with Fragile X syndrome, such as anxiety.
Zygel is a pharmaceutically produced CBD, a non-psychoactive cannabinoid, which is applied as a gel to the skin. CONNECT-FX is a placebo-controlled trial, and folllows a smaller trial conducted in Melbourne, Sydney and Brisbane in 2017.
The current study hopes to recruit approximately 200 participants aged between 3 and 17 across Australia, New Zealand and the US.
There is more detailed information on the trial, on the National Fragile X Foundation (US) website:
Trial contacts in Australia:
MELBOURNE: Dr Jonathan Cohen, Fragile X Alliance Clinic, 03 9528 1910. email@example.com
SYDNEY: Dr Natalie Silove, Westmead Children’s Hospital, 02 9845 1413. SCHN-ClinicalTrials@health.nsw.gov.au
BRISBANE: Dr Honey Heussler 07 3069 7709 firstname.lastname@example.org